Our Team And The Power of imagination

Mehmood Khan, MD

Chief Executive Officer

Mehmood Khan, MD, is Chief Executive Officer and Board Member of Life Biosciences Inc. In his role as CEO, Dr. Khan provides strategic direction and operational oversight across Life Biosciences and its six daughter companies. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology that Life Biosciences advances. By leveraging his diverse experience in pharmaceutical, clinical, and consumer industries, Dr. Khan is the ideal leader for Life Biosciences through its evolution and emergence as a global leader in longevity research and product development. Dr. Khan previously served as Global Vice Chairman and Chief Scientific Officer of PepsiCo. He played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw their global sustainability initiatives. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue. Before moving into industry, Dr. Khan had a distinguished medical career as a practicing faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. Dr. Khan is a member of the Board of Directors of Reckitt Benckiser, National Institute of Standards and Technology (NIST), and Indigo Ag. He also serves as Chair of the U.S. Council on Competitiveness. Dr. Khan earned his medical degree from the University of Liverpool Medical School, England and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians, London, a Fellow of the American College of Endocrinology, and holds two ad honorem PhDs in humanities and international law. He has been exclusively featured in numerous publications including Fast Company's 100 Most Creative People in Business.

Tristan Edwards

Co-Founder, President & Chief Investment Officer

Tristan Edwards is Co-founder, President, and Chief Investment Officer of Life Biosciences. He also sits on the Boards of Continuum Biosciences, Animal Biosciences, Senolytic Therapeutics, and Jumpstart Fertility. Tristan brings extensive global financial capital markets, regulatory compliance, and fiduciary oversight experience to the group, following a 16-year investment career spanning leading financial organizations across Australia, London, HK, and Singapore. Having recognized the opportunity to leverage this experience in an entrepreneurial environment, he has subsequently moved to pursue his passion for helping create a scalable platform for financing and enabling the world’s best scientists and thought leaders to create change. Tristan’s professional background has been in senior investment roles at leading financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital, and Mosaic Asset Management. He started his career with the Australian Commonwealth Department of Finance. Tristan has a degree in commerce from the University of Tasmania, and held the CFA, CMT and CPA designations.

David Sinclair

David A. Sinclair, PhD, AO

Co-Founder

David A. Sinclair PhD, AO is Co-founder at Life Biosciences. He is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research. Dr. Sinclair is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious, and rare diseases. Dr. Sinclair’s work has been featured in five books, two documentary movies, on CBS 60 Minutes, in Morgan Freeman’s “Through the Wormhole” and more. He has received more than 35 awards for his medical research, innovation, and teaching. In 2014, he was named as TIME’s “100 Most Influential People in the World”, TIME’s “50 Most Influential People in Health Care” in 2018 and was appointed an Officer of the Order of Australia. He serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award.

John Amatruda, MD

President, Life Laboratories

Dr. John Amatruda is President of Life Laboratories, a division of Life Biosciences, and a member of Life's Scientific Advisory Board. Throughout his 26-year career in drug research and development, Dr. Amatruda has produced drugs that treat diabetes, obesity, cardiovascular disease and more. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he also co-founded the biotech company CohBar, served on numerous scientific advisory panels and Boards of Directors and was a Vice President at Bayer Corp and a Senior Vice President at Merck Pharmaceuticals. A prolific author, Dr. Amatruda has published over 150 papers, abstracts, reviews, and book chapters, primarily on diabetes and cardiovascular disease. Dr. Amatruda received a BA from Yale University, an MD from the Medical College of Wisconsin, and completed clinical training in medicine and fellowship in endocrinology and metabolism at the Johns Hopkins Hospital.

Amit Shashank

General Counsel

Amit Shashank is a strategically-oriented global leader, with more than twenty years of international experience in technology and business services organizations. As General Counsel, he oversees Life Biosciences’s government affairs, legal, and compliance initiatives. Amit is a leader in navigating complex regulatory approvals and developing global strategic alliances that span mergers and acquisitions, commercial transactions, and all phases of corporation financings. On two separate occasions, Amit has led companies toward commercializing and liquidity events which include initial public offerings (IPO). Most recently, Amit served as Executive Vice President, General Counsel and Secretary of Aricent, a global R&D engineering and design powerhouse, which under his leadership as part of the executive team, grew to over 10,000 employees. In 2018, Amit was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies (EPA: ALT) for $2 billion. Prior to Aricent, Amit served as Executive Vice President, General Counsel, Chief Compliance Officer, and Secretary at ExlService Holdings, Inc. (NASDAQ: EXLS), an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company. Amit began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law. Amit is also a Rhodes Scholar and an adjunct professor at Columbia University Law School.

Nick Ventresca

CTO

Nick Ventresca is the Chief Technology Officer at Life Biosciences. Nick brings over 20 years’ experience in Information Technology (IT) for large multi-national organizations, mid-sized biopharmas, and startup biotechs. Nick has broad international expertise implementing innovative scientific and patient-centric technology. Most recently, he grew strategic IT solutions for late-stage biotechs now commercializing. Previously, he served as CIO for high-profile organizations including Ariad (now Takeda), Genzyme (now Sanofi), Charles River Laboratories, Visiting Nurse Service of New York and Warner Lambert (now Pfizer), and was Chief Technology Officer for Pepsi Cola International. Nick is a graduate of Fordham University with a BS in biology and studied for two years at the La Sapienza School of Medicine in Rome, Italy.

Brian Malone, FCA

CFO

Brian Malone is Chief Financial Officer at Life Biosciences. Brian brings over 35 years of experience in financial services, working with investment firms in Ireland, London and Boston. Brian was the Chief Financial Officer of Longwood Fund Management and also served as the first CFO/COO of many of the companies that Longwood incubated including some that went on to be NASDAQ listed. Most recently, he was the Senior Vice President of Finance at Axial Biotherapeutics, Inc., where he was responsible for all aspects of finance, operations, and information technology. Brian has an Honors Degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. He recently completed a post-graduate course in strategy for pharma and biotech industries.

David Setboun, PharmD, MBA

Vice President

David Setboun brings 20 years of experience in general management and commercial for biopharma companies in Europe and Americas. Previously, he served as VP and General Manager for Biogen France. Prior to his work at Biogen, he held different senior executive positions at AstraZeneca, Eli Lilly, and Sanofi. He brought to market numerous treatments and technologies across a broad range of therapeutic areas. He holds a PharmD from Paris XI University and an HEC MBA & Advance Management Program from Harvard Business School.

Frances Toneguzzo, PhD

Head of Intellectual Property

Dr. Frances Toneguzzo is Head of Intellectual Property at Life Biosciences. She leads with an extensive skill set in technology evaluation, business development, and licensing. Dr. Toneguzzo has a background in negotiating deals with life sciences companies, and is a strategic thinker and driver of new initiatives designed to stimulate, support and sustain innovation. She previously served as Executive Director at Partners Healthcare, Harvard University, and Tufts University. She is also seasoned in the financing and management of startup companies, co-founding the biotech company Dyrnamix Inc. She received her PhD in biochemistry from McMaster University.

Sree Kant, MBA, MPH

Head of Business Development

Sree Kant heads business development at Life Biosciences and is focused on new scientific investments and strategic partnerships. Sree comes to Life with 18 years of varied healthcare and pharmaceutical industry experience. He previously was the head of early partnering strategy for Pfizer, working across different therapeutic areas/technologies and geographies with Academia, VCs/Banks, CROs, and other strategic partners. Sree was also a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. He has an MBA from the Indian Institute of Management and an MPH from the Harvard School of Public Health. Sree is an invited speaker at key industry events and conferences on subjects of R&D strategy, innovative partnering models, industry-academia collaborations, early-stage technologies and investments, etc.

Michael Ringel, PhD, JD

Strategic Advisor

Dr. Michael Ringel is Strategic Advisor at Life Biosciences. Dr. Ringel has 20 years of experience focused on corporate development, partnering, and R&D innovation. He is concurrently a Senior Partner and Managing Director at The Boston Consulting Group, where he is the Global Topic Leader for Research and Product Development. Dr. Ringel is a frequent contributor to industry journals and a popular public speaker, including having a TED talk on biopharma R&D partnering. Dr. Ringel has a BA in biology summa cum laude from Princeton University, a PhD in biology from Imperial College, and a JD cum laude from Harvard Law School.

Ivan Kaplan, JD

Corporate Counsel

Ivan Kaplan is the Corporate Counsel at Life Biosciences. He’s a practicing corporate governance and securities attorney who has previously served as an associate at Wilson Sonsini Goodrich & Rosati, where he counseled clients on corporate transactions and general corporate governance matters. Prior to law school, Ivan served as a legislative staffer for two members of Congress. He holds an MBA from the University of Chicago Booth School of Business and a JD from the Northwestern University Pritzker School of Law.

Marc Ramis Castelltort, PhD

Co-founder and CEO, Senolytic Therapeutics

Dr. Marc Ramis-Castelltort is Co-founder and CEO of Senolytic Therapeutics, a pharmaceutical company that develops a novel class of medicines by targeting damaged cells. He is an advisor for Life Biosciences Inc. in Europe helping to scout novel aging-associated ventures. Dr. Ramis-Castelltort's experience spans academia and the business world. He has had an impressive and wide-ranging career, from co-founding and leading pharmaceutical, academic, and venture capital firms, such as Senolytic Therapeutics, Cebiotex and Chasing Science, to working with premier research institutions such as Cancer Research UK, Oxford University Innovation and IRB Barcelona. The companies he’s built and advised have created drug-delivery nano-systems for cancer, brokered corporate-academic partnerships, and more. Dr. Ramis-Castelltort’s academic degrees include a PhD in biochemistry from the University of Oxford, a Harvard Business School PLD Program, an MS in chemical engineering and a BS in chemistry from IQS in Barcelona.

Doug Korn, MBA

CEO, Animal Biosciences

Doug Korn is the CEO of Animal Biosciences. He most recently served as Vice President of Strategy for Mars Petcare North America where he helped lead the $4B North American division of the world’s largest pet care company, with over 3,500 associates and 20 manufacturing locations. During his seven years at Mars, the business achieved record performance with sustainable growth, improved earnings, and market share growth. Doug was directly responsible for the company’s strategic plan, corporate and portfolio strategy and business development. Prior to his time at Mars, he worked in sales and marketing at The Clorox Company and Procter & Gamble. He holds a BS in chemical engineering from Lafayette College, a MBA from Boston College, and a ThM from Liberty University.

Simon Tucker, PhD

CEO, Jumpstart Fertility and Continuum Biosciences

Dr. Simon Tucker brings decades of experience in pharmaceutical research and development and management as CEO of both Jumpstart Fertility Inc. and Continuum Biosciences Inc. He previously worked at GD Searle, USA, helping make key discoveries leading to the development of a treatment for HIV infection. He was later Vice President of Research at Biota Pharmaceuticals (now Vaxart), where he was responsible for their entire intellectual property and research portfolio. In 2015, he founded and was CEO of the successful contract research organization, 360biolabs. Dr. Tucker has a BS in biochemistry from the University of Sussex and a PhD from the University of Reading.

Ray Pawlicki

Chair, Technology Advisory Board

Raymond Pawlicki is Chair of the Technology Advisory Board at Life Biosciences where he is creating a world-class, next generation technology platform. Formerly the Chief Information Officer at Biogen, Ray was instrumental in transforming IT, pivotal to the company’s success. Prior to Biogen, he worked for eight years at Novartis Pharmaceuticals, A.G., serving as both CIO of the US affiliate and Global CIO of the Switzerland-based, $27 billion enterprise. Ray is a Director and Member of Finance Committee for Harvard Pilgrim, one of the nation’s leading health services companies that serves 2.7 million members, and is Chairman of the IT Subcommittee of the Board of Trustees for UMass Memorial Healthcare. Ray has a BS in computer science from Montclair State University.

Lawrence Gozlan

Strategic Advisor

Lawrence Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively in life sciences. With 18 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities. Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte. Lawrence currently serves as a Director on the Board of Nohla Therapeutics, Prana Biotechnology (NASDAQ: PRAN) and Ausbiotech, Australia’s biotechnology industry association. He holds a BS with Honors in immunology from the University of Melbourne.